Biomarkers of dementia: Comparison of electrochemiluminescence results and reference ranges with conventional ELISA

Regeniter, Axel; Kuhle, Jens; Baumann, Thomas; Sollberger, Marc; Herdener, Marcus; Kunze, Ursula; Camuso, Michael C.; Monsch, Andreas U.

doi:10.1016/j.ymeth.2012.03.019

Cited by 11 publications

(6 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While both our study and Hampel et al used similar CSF P-tau231 assay procedures, our results are not consistent with those of Regeniter et al [22] who used the Meso Scale Diagnostics (MSD) platform in a multiplex format to assay P-tau231. Regeniter et al reported that only about 35% (55/156) of their 156 subjects’ MSD P-tau231 samples were in a detectable range.…”

Section: Discussioncontrasting

confidence: 99%

Greater Specificity for Cerebrospinal Fluid P-tau231 over P-tau181 in the Differentiation of Healthy Controls from Alzheimer’s Disease

Spiegel

Pirraglia

Osorio

et al. 2015

JAD

View full text Add to dashboard Cite

Cerebrospinal fluid (CSF) measures of phosphorylated-tau (P-tau) 231 and P-tau181 are two biomarkers for the identification of tau pathology as related to Alzheimer’s disease (AD). While both are pathologically validated, their relative diagnostic performances are not well known. This cross-sectional diagnostic study of 87 normal (NL) subjects and 28 AD subjects compared CSF P-tau231 with CSF P-tau181. Logistic regression modeling demonstrated that the P-tau231 was superior to the P-tau181 in the diagnostic classifications. At a fixed 85% sensitivity cutoff, the ROC analysis shows that P-tau231 has greater overall specificity than P-tau181. While both P-tau analytes demonstrated equivalent negative predictive accuracies, P-tau231 yielded significantly fewer false positives. Moreover, P-tau231, but not P-tau181, demonstrated sensitivity to the E4 genotype. A postmortem validation with 9 AD subjects confirmed the superiority of the CSF P-tau231 specificity. This study suggests that P-tau231 has the potential to improve the CSF tau biomarker diagnosis of AD.

show abstract

Section: Discussioncontrasting

confidence: 99%

Greater Specificity for Cerebrospinal Fluid P-tau231 over P-tau181 in the Differentiation of Healthy Controls from Alzheimer’s Disease

Spiegel

Pirraglia

Osorio

et al. 2015

JAD

View full text Add to dashboard Cite

show abstract

“…For example, a new approach that used immunoprecipitation to pull down various Aβ fragments in plasma samples followed by mass-spectrophotometry analysis has led to discovery of a new marker, APP669–711, whose ratio to Aβ1-42 demonstrated 93% sensitivity and 96% specificity to discriminate Pittsburgh compound B (PIB)-positive subjects from PIB-negative subjects [58]. New immunoaffinity-based assays have also been applied to AD core marker analysis in biofluids, including immunomagnetic reduction (IMR) and single molecule array (SIMOA) for the analysis of plasma samples and the assay by Meso Scale Discovery (Rockville, MD) for CSF samples [59]. Here, we limit the scope of this review to the IMR and SIMOA assays, which have been used to quantify plasma Aβ and tau in studies involving medium to large numbers of subjects.…”

Section: Ultra-sensitive Technologiesmentioning

confidence: 99%

Amyloid Beta and Tau as Alzheimer’s Disease Blood Biomarkers: Promise From New Technologies

2017

View full text Add to dashboard Cite

The utility of the levels of amyloid beta (Aβ) peptide and tau in blood for diagnosis, drug development, and assessment of clinical trials for Alzheimer’s disease (AD) has not been established. The lack of availability of ultra-sensitive assays is one critical issue that has impeded progress. The levels of Aβ species and tau in plasma and serum are much lower than levels in cerebrospinal fluid. Furthermore, plasma or serum contain high levels of assay-interfering factors, resulting in difficulties in the commonly used singulex or multiplex ELISA platforms. In this review, we focus on two modern immune-complex-based technologies that show promise to advance this field. These innovative technologies are immunomagnetic reduction technology and single molecule array technology. We describe the technologies and discuss the published studies using these technologies. Currently, the potential of utilizing these technologies to advance Aβ and tau as blood-based biomarkers for AD requires further validation using already collected large sets of samples, as well as new cohorts and population-based longitudinal studies.

show abstract

“…Concentrations were obtained by fitting the data to a standard curve using nonlinear 3-factor regression. MSD analysis was performed as previously described (52). High-binding carbon electrodes were set in the bottom of microplates and MSD assays used electrochemiluminescent labels that are conjugated to detection antibodies (SULFO-TAG) and allow for sensitive detection.…”

Section: Locus (Rosa26mentioning

confidence: 99%

CD44 expression in endothelial colony-forming cells regulates neurovascular trophic effect

et al. 2017

View full text Add to dashboard Cite

Biomarkers of dementia: Comparison of electrochemiluminescence results and reference ranges with conventional ELISA

Cited by 11 publications

References 28 publications

Greater Specificity for Cerebrospinal Fluid P-tau231 over P-tau181 in the Differentiation of Healthy Controls from Alzheimer’s Disease

Greater Specificity for Cerebrospinal Fluid P-tau231 over P-tau181 in the Differentiation of Healthy Controls from Alzheimer’s Disease

Amyloid Beta and Tau as Alzheimer’s Disease Blood Biomarkers: Promise From New Technologies

CD44 expression in endothelial colony-forming cells regulates neurovascular trophic effect

Contact Info

Product

Resources

About